Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 7 |
| List of Tables | 5 | 3 |
| List of Figures | 8 | 2 |
| Women s Health Therapeutics Market to 2017 - Introduction | 10 | 2 |
| GBI Research Report Guidance | 11 | 1 |
| Women s Health Therapeutics Market to 2017 - Market Overview | 12 | 9 |
| Introduction | 12 | 1 |
| Revenue Forecasts for Women s Health Therapeutics Market | 12 | 1 |
| Revenues | 12 | 2 |
| Geographical Segmentation | 14 | 2 |
| Annual Cost of Therapy | 16 | 1 |
| Generic Share | 17 | 1 |
| Treatment Usage Patterns | 18 | 2 |
| Drivers and Barriers for Women s Health Therapeutics Market | 20 | 1 |
| Drivers for Women s Health Therapeutics Market | 20 | 1 |
| Introduction of First-In-Class Therapies with Better Safety and Efficacy | 20 | 1 |
| Increase in Treatment Seeking Population Due To Increasing Awareness about Women s Health Disorders | 20 | 1 |
| Barriers for Women s Health Therapeutics Market | 20 | 1 |
| Availability of Alternative Treatment Options Such As Yoga, Physiotherapy and Other Lifestyle Changes | 20 | 1 |
| Women s Health Therapeutics Market to 2017 - Geographical Landscape | 21 | 12 |
| The US | 21 | 1 |
| Revenue | 21 | 1 |
| Annual Cost of Therapy | 22 | 1 |
| Treatment Usage Pattern | 23 | 2 |
| Top Five Countries of Europe | 25 | 1 |
| Revenue | 25 | 1 |
| Annual Cost of Therapy | 26 | 1 |
| Treatment Usage Pattern | 27 | 2 |
| Japan | 29 | 1 |
| Revenue | 29 | 1 |
| Annual Cost of Therapy | 30 | 1 |
| Treatment Usage Pattern | 31 | 2 |
| Women s Health Therapeutics Market to 2017 - Therapeutic Landscape | 33 | 42 |
| Menopause | 33 | 1 |
| Introduction | 33 | 1 |
| Hormone Therapy and the Women s Health Initiative Study | 33 | 1 |
| Revenues | 34 | 2 |
| Geographical Segmentation | 36 | 2 |
| Generic Share | 38 | 1 |
| Annual Cost of Therapy | 39 | 1 |
| Treatment Usage Patterns | 40 | 2 |
| Drivers and Barriers for Menopause | 42 | 1 |
| Drivers for the Menopause Therapeutics Market | 42 | 1 |
| Barriers for the Menopause Therapeutics Market | 42 | 1 |
| Post Menopausal Osteoporosis | 43 | 1 |
| Introduction | 43 | 1 |
| Revenues | 44 | 1 |
| Geographical Segmentation | 45 | 2 |
| Generic Share | 47 | 1 |
| Annual Cost of Therapy | 48 | 1 |
| Treatment Usage Patterns | 49 | 2 |
| Treatment Flow Algorithm | 51 | 1 |
| Drivers and Barriers for Post Menopausal Osteoporosis | 52 | 1 |
| Drivers for the Post Menopausal Osteoporosis Therapeutics Market | 52 | 1 |
| Barriers for the Post Menopausal Osteoporosis Therapeutics Market | 52 | 1 |
| Endometriosis | 53 | 1 |
| Introduction | 53 | 1 |
| Revenues | 54 | 1 |
| Geographical Segmentation | 55 | 2 |
| Generic Share | 57 | 1 |
| Annual Cost of Therapy | 58 | 1 |
| Treatment Usage Patterns | 59 | 2 |
| Treatment Flow Algorithm | 61 | 1 |
| Drivers and Barriers for Endometriosis | 62 | 1 |
| Drivers for the Endometriosis Therapeutics Market | 62 | 1 |
| Barriers for the Endometriosis Therapeutics Market | 62 | 1 |
| Urinary Incontinence | 63 | 1 |
| Introduction | 63 | 2 |
| Revenues | 65 | 1 |
| Geographical Segmentation | 66 | 2 |
| Generic Share | 68 | 1 |
| Annual Cost of Therapy | 69 | 2 |
| Treatment Usage Patterns | 71 | 2 |
| Treatment Flow Algorithm | 73 | 1 |
| Drivers and Barriers for Urinary Incontinence | 74 | 1 |
| Drivers for Urinary Incontinence Market | 74 | 1 |
| Barriers for Urinary Incontinence Market | 74 | 1 |
| Women s Health Therapeutics Market to 2017 - Pipeline Analysis | 75 | 14 |
| Introduction | 75 | 2 |
| Research and Development Pipeline - Menopause | 77 | 1 |
| Research and Development Pipeline - Postmenopausal Osteoporosis | 78 | 2 |
| Research and Development Pipeline - Endometriosis | 80 | 1 |
| Research and Development Pipeline - Urinary Incontinence | 81 | 1 |
| Profiles of Promising Drugs in the Women s Health Therapeutics Market | 82 | 1 |
| Aprela (Bazedoxifene/Conjugated Estrogen) | 82 | 1 |
| Overview | 82 | 1 |
| Efficacy | 82 | 1 |
| Safety | 82 | 1 |
| Clinical Study Details | 83 | 1 |
| Pristiq (Desvenlaxafine, DVS-233) | 83 | 1 |
| Overview | 83 | 1 |
| Efficacy | 83 | 1 |
| Safety | 83 | 1 |
| Clinical Studies | 84 | 1 |
| Visanne | 84 | 1 |
| Overview | 84 | 1 |
| Efficacy | 84 | 1 |
| Safety | 84 | 1 |
| Clinical Study Details | 84 | 1 |
| Elagolix (NBI-56418) | 85 | 1 |
| Overview | 85 | 1 |
| Efficacy | 85 | 1 |
| Safety | 85 | 1 |
| Clinical Study Details | 85 | 1 |
| Odanacatib (MK-0822) | 85 | 1 |
| Overview | 85 | 1 |
| Efficacy | 85 | 1 |
| Safety | 86 | 1 |
| Clinical Study Details | 86 | 1 |
| Viviant (Bazedoxifene) | 86 | 1 |
| Overview | 86 | 1 |
| Efficacy | 86 | 1 |
| Safety | 86 | 1 |
| Clinical Study Details | 86 | 1 |
| YM178 | 87 | 1 |
| Overview | 87 | 1 |
| Efficacy | 87 | 1 |
| Safety Profile | 87 | 1 |
| Clinical Study Details | 87 | 1 |
| GRC 6211 | 88 | 1 |
| Overview | 88 | 1 |
| Efficacy | 88 | 1 |
| Safety Profile | 88 | 1 |
| Clinical Study Details | 88 | 1 |
| Women s Health Therapeutics Market to 2017- Competitive Landscape | 89 | 7 |
| Market Share Analysis - Women s Health Therapeutics Market | 89 | 1 |
| Major Marketed Products: Women s Health Therapeutics Market | 90 | 1 |
| Detrol (tolterodine tartrate) | 90 | 1 |
| Overview | 90 | 1 |
| Premarin | 90 | 1 |
| Overview | 90 | 1 |
| Evista (raloxifene hydrochloride) | 90 | 1 |
| Overview | 90 | 1 |
| Actonel (Risedronate sodium) | 90 | 1 |
| Overview | 90 | 1 |
| Competitive Profiling | 91 | 1 |
| Pfizer | 91 | 1 |
| Overview | 91 | 1 |
| SWOT Profile | 91 | 1 |
| Eli-Lilly | 92 | 1 |
| Overview | 92 | 1 |
| SWOT Profile | 92 | 1 |
| Merck | 93 | 1 |
| Overview | 93 | 1 |
| SWOT Profile | 93 | 1 |
| Roche | 94 | 1 |
| Overview | 94 | 1 |
| SWOT Profile | 94 | 1 |
| Warner Chilcott | 95 | 1 |
| Overview | 95 | 1 |
| SWOT Profile | 95 | 1 |
| Women s Health Therapeutics Market to 2017 - M&A Landscape | 96 | 11 |
| M&A Landscape | 96 | 1 |
| M&A Deals by Year | 96 | 1 |
| M&A Deals by Deal Type | 97 | 1 |
| M&A Deals by Geography | 98 | 1 |
| M&A Deals by Value | 99 | 1 |
| Top Five M&A Deals by Value | 100 | 1 |
| R&D Licensing Agreements | 101 | 1 |
| Deals by Year | 101 | 1 |
| Deals by Geography | 102 | 1 |
| Deals by Value ($) | 103 | 1 |
| Co-Development Agreements | 104 | 1 |
| Co-Development Agreements by Year | 104 | 1 |
| Co-Development Agreements by Geography | 105 | 1 |
| Co-Development Agreements by Value | 106 | 1 |
| Women s Health Therapeutics Market to 2017 - Appendix | 107 | 8 |
| Market Definitions | 107 | 1 |
| Abbreviations | 107 | 1 |
| Research Methodology | 108 | 6 |
| Coverage | 108 | 1 |
| Secondary Research | 108 | 1 |
| Primary Research | 109 | 1 |
| Section Wise Methodology | 109 | 1 |
| Therapeutic Landscape | 109 | 3 |
| Geographical Landscape | 112 | 1 |
| Pipeline Analysis | 113 | 1 |
| Competitive Landscape | 113 | 1 |
| Expert Panel Validation | 113 | 1 |
| Contact Us | 113 | 1 |
| Disclaimer | 113 | 1 |
| Sources | 113 | 2 |